# 2026-04196: FDA Asks Drug Makers: How to Scale Without Breaking Rules

2026-04196, Recommendations on Scale-Up and Postapproval Changes Guidances for Industry; Request for Comments, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2026-03-03, effective Submit either electronic or written comments on the notice by June 1, 2026 to ensure that the Agency considers your comment on these guidance documents before it begins work on any revisions.; PRIA reads it as touching household money (as of 2026-06-08).

- Canonical: https://policyrisk.com/federal-register/2026-04196
- As of: 2026-06-08
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-04196
- Title: Recommendations on Scale-Up and Postapproval Changes Guidances for Industry; Request for Comments
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 10397
- Published: 2026-03-03
- Effective: Submit either electronic or written comments on the notice by June 1, 2026 to ensure that the Agency considers your comment on these guidance documents before it begins work on any revisions.
- Comments close: 2026-06-01
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-06-08

## In one line

FDA Asks Drug Makers: How to Scale Without Breaking Rules

## Summary

The FDA wants to hear from drug makers and the public about how to improve their rules for making and changing certain medicines after approval. These rules help companies safely scale up production and tweak products without delays. Comments are open until June 1, 2026, so get your ideas in to help shape future guidance and keep medicine manufacturing smooth and cost-effective.

## Abstract

The Food and Drug Administration (FDA, the Agency, or we) is announcing the opening of a public docket to solicit information and comments on the Agency's series of guidances for industry on scale-up and postapproval changes (SUPAC) for specific dosage forms. Specifically, we are seeking comment on the following guidances for industry: "Immediate Release Solid Oral Dosage Forms Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and Controls, In Vitro Dissolution Testing, and In Vivo Bioequivalence Documentation" (SUPAC- IR); "SUPAC-IR Questions and Answers about SUPAC-IR Guidance" (SUPAC- IR Q&A); "Nonsterile Semisolid Dosage Forms Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and Controls; In Vitro Release Testing and In Vivo Bioequivalence Documentation" (SUPAC-SS); "SUPAC- MR: Modified Release Solid Oral Dosage Forms Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and Controls; In Vitro Dissolution Testing and In Vivo Bioequivalence Documentation" (SUPAC-MR); and "SUPAC: Manufacturing Equipment Addendum" (SUPAC-MEA). The Agency is seeking public information and comment on the continued utility of and suggestions for potential revisions to the recommendations in these guidances.

## Effects PRIA read

- FDA Opens Public Docket on SUPAC: benefit, low. The FDA opened a public docket requesting information and comments on its SUPAC guidances and related documents. You can submit comments electronically or by mail and must do so by June 1, 2026, for the Agency to consider them before it begins work on any revisions.
- SUPAC Reduces Approval Delays and Saves Industry: benefit, high. The SUPAC guidances are intended to reduce the number of chemistry, manufacturing, and controls (CMC) changes that require supplemental FDA approval. This can minimize delays in product distribution, give manufacturers more control over production resources, and result in significant net savings to…
- FDA May Update SUPAC to Reflect New Science: benefit, medium. The FDA is considering updating the SUPAC guidances to align with evolving science and other guidances (for example, ICH Q12) to improve their utility and effectiveness. These updates are intended to help manufacturers more effectively evaluate CMC changes within their quality systems before submit…

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2026-04196 on federalregister.gov](https://www.federalregister.gov/documents/2026/03/03/2026-04196/recommendations-on-scale-up-and-postapproval-changes-guidances-for-industry-request-for-comments)
- [2026-04196 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-03-03/pdf/2026-04196.pdf)

## Related
- [Previous: 2026-04195, Submission for OMB Review; Comment Request](https://policyrisk.com/federal-register/2026-04195)
- [Next: 2026-04197, Certain Freight Rail Couplers and Parts Thereof from India: Preliminary Affirma…](https://policyrisk.com/federal-register/2026-04197)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-04196 (as of 2026-06-08).
